PSU Insurers Grew 6% While Standalone Health Grew 29%: Time to Re-cut the Group Health Panel

A Kotak Institutional Equities note reported by ANI and The Tribune on 20 August 2026 put July 2026 growth for standalone health insurers at 29 per cent, against 6 per cent for public sector general insurers. Asia Insurance Post reported in August 2026 that the seven standalone health insurers together grew premium income by 30 per cent to Rs 4,666 crore in July 2026. Over the same period, private general insurers held approximately 51 per cent market share, up 70 basis points year on year on Kotak's numbers.

A five-times growth gap between two sets of carriers in the same month reflects where new health business is being written, which is a proxy for where appetite and product investment are going. For a corporate whose group mediclaim has renewed with the same public sector insurer for eight or ten years, that is a question about the counterparty.

The practical concern is straightforward. An insurer whose health book is growing at 6 per cent while the segment leaders grow at 29 per cent is either deliberately shedding unprofitable group business, losing it to competitors, or both. Group mediclaim for a mid-sized corporate is frequently the least profitable part of a general insurer's health book, so it is the first place a shrinking insurer prunes. A corporate finds out through the renewal quote: a loading it did not expect, a sub-limit that was not there last year, a room-rent cap reintroduced, or a flat refusal to continue a dependent-parent cover that had been in place for years.

None of that is a reason to change insurers reflexively. It is a reason to run a structured panel review rather than a renewal negotiation, so the decision to stay or move rests on tested criteria instead of inertia.

Premium growth is a lagging indicator of underwriting appetite, but for group health it lags by only a renewal cycle or two. Reading it correctly means separating three different things that all look like slow growth.

Deliberate de-risking. An insurer may be growing slowly because it has decided its group health loss ratios are unsustainable and is repricing the book upward while letting the worst accounts leave. This is rational behaviour and it produces a hard but honest renewal: a large rate increase, tighter terms, and a willingness to walk. A corporate facing this insurer is being told, accurately, what its own claims experience costs.

Distribution and product lag. An insurer may be growing slowly because its product set and servicing are behind. Standalone health insurers built their entire business around one line, which shows in network contracting, cashless infrastructure, wellness add-ons and plan-design flexibility. A general insurer running health as one of eight lines competes for internal capital against motor, fire and marine. When health growth diverges as sharply as it did in July 2026, product and servicing lag is usually part of the explanation.

Capacity constraint. An insurer may be growing slowly because its solvency position limits how much new business it can absorb. This is the most consequential case, because it affects the insurer's ability to pay as well as its willingness to quote.

The three look identical from the outside. Distinguishing them is the first job of a panel review, and it is done by asking the insurer directly, in writing, at the pre-renewal meeting: what is your appetite for group health in our sector and size band for the next two years, and has your retention target on group mediclaim changed. An insurer that is deliberately pruning will usually say so. One that is capacity constrained will be vaguer, and the solvency position filed with the IRDAI becomes the thing to check independently.

The common failure in a group health panel review is going straight to a request for quotations. Three or four insurers respond with rates on slightly different plan constructions, procurement picks the lowest number, and the corporate discovers at claim time that the cheapest quote carried a co-payment or a disease-wise sub-limit the comparison did not surface.

The review should run in four stages, in order.

1. Fix the specification first. Write the plan design the corporate actually wants (sum insured bands, family definition, parental cover, maternity limits, pre-existing disease waiting period waiver, room-rent basis, corporate buffer) and issue it as a fixed specification. Every insurer quotes the same construction. Deviations are listed separately as an insurer's own proposal, priced separately, and compared on merit.
2. Disclose claims data completely. Three years of claims data, incurred and paid, with claim counts, average claim size, top diagnoses and the incurred-claims ratio calculated on the same basis for each year. Incomplete disclosure produces indicative quotes that get revised upward after the corporate has committed.
3. Score on tested criteria, not just rate. The financial, service and network tests set out in the next three sections carry defined weights agreed before the quotes arrive.
4. Test the incumbent on the same basis. The incumbent insurer participates as a candidate, not as a default. Its quote is scored against the same criteria as every challenger.

Fixing the specification first matters because group mediclaim policy wordings differ more than the headline plan summary suggests. Two insurers quoting the same sum insured and room-rent basis can differ on how they define a day-care procedure, whether the corporate buffer is drawn automatically or on approval, and how proportionate deduction applies on a room upgrade. Those differences are where the recovery is won or lost, and they are only visible in the wording.

For group health, the counterparty test differs in emphasis from a property or liability programme. Claim frequency is high and individual claim size is modest, so the risk is less about funding a catastrophic loss and more about whether the insurer's capital position is squeezing operational spend on claims handling and network management.

Two checks do most of the work for group health.

• Solvency ratio, level and trend. The IRDAI requires every insurer to maintain a minimum solvency ratio at all times. Ask each candidate for its current position and the figures for the preceding reporting periods. A carrier comfortably and stably above the minimum is a different counterparty from one hovering near the floor, even though both technically comply.
• Health segment performance, separately from the total book. A general insurer's overall combined ratio can be respectable while its health segment runs at a loss subsidised by other lines. That is exactly the configuration that produces sudden appetite withdrawal at renewal. Ask for the health segment's incurred claims ratio.

Growth and capital interact, which is why the July 2026 divergence matters here. Neither position is inherently safer. A rapidly growing standalone health insurer may have recent capital raises and a young claims book that has not yet matured; a slow-growing public sector insurer may have a mature book with known experience. The corporate is assessing which risk it prefers, and it needs the numbers to do so.

The counterparty vetting framework for insurer financial security applies here in condensed form: solvency first as a filter, independent ratings as corroboration, and claims behaviour as the thing that actually determines the experience.

The service test is where a group health panel review earns its cost, because it is the dimension employees experience and the one the corporate's HR function is judged on internally.

The IRDAI Annual Report 2024-25 records that insurers rejected about 8 per cent of the 3.26 crore health claims they handled in FY25, roughly one claim in twelve. That is a market aggregate. A candidate's rejection rate materially above it is worth investigating, and so is one suspiciously below it, which sometimes reflects claims classified as withdrawn or closed for want of documents rather than rejected.

Ask each candidate insurer, in writing, for:

• Cashless pre-authorisation turnaround, measured from receipt of a complete request to the authorisation decision, with the distribution rather than only the average.
• Reimbursement claim settlement turnaround from receipt of complete documents to payment.
• Rejection rate and repudiation rate on group health for the preceding financial year, with the top three grounds of rejection by count.
• Grievance volumes and average resolution time on group health.
• Whether claims are handled in-house or through a third party administrator, and if the latter, which one.

The last question deserves weight of its own. A corporate that changes insurer may find the TPA handling its claims is the same one it had before, or that a strong insurer has been paired with a weak administrator. The insurer's claims reputation and the TPA's servicing quality are separable, and both need testing.

Regulatory pressure on this dimension is increasing. Whalesbook reported in July and August 2026 that the IRDAI has tightened rules linking key management personnel remuneration, including chief executives, to defined performance parameters such as claims settlement speed and grievance redressal. That moves claims turnaround from an operational metric a service head owns into a number that affects senior executive pay. A corporate running a panel review in the 2026-27 cycle can reasonably ask each candidate how it measures itself against those parameters and expect an answer. The broader shift in service standards and turnaround norms is the backdrop against which the answers should be read.

Network size is the most quoted and least useful number in a group health comparison. An insurer claiming a network of 12,000 hospitals and one claiming 9,000 are not meaningfully different if the corporate's workforce is concentrated in four cities and the relevant question is which tertiary-care hospitals in those four cities offer cashless at negotiated rates.

The test that produces a usable answer has three parts.

1. Map the workforce, then map the network against it. For each employee concentration, list the hospitals employees actually use, drawn from the past three years of claims data, and ask each candidate insurer to confirm hospital by hospital whether it is in the cashless network and at what tariff arrangement.
2. Check the exclusion list, not just the inclusion list. Insurers periodically suspend or delist hospitals over billing disputes or fraud investigations. A hospital that is technically in the network but currently suspended is not available to an employee. Ask for the current list of suspended or excluded providers in the corporate's key locations.
3. Test the tariff arrangement, not just the presence. A hospital in the network without a negotiated package rate leaves the employee exposed to whatever the hospital bills, subject to the policy's reasonable-and-customary provisions and any sub-limits on the sum insured. A hospital with negotiated package rates for the common procedures produces a predictable outcome.

The comparison between standalone health insurers and general insurers on group business turns substantially on this point, and it is genuinely account-specific. A corporate with employees across thirty tier-two locations has a different answer from one with 2,000 employees in two metros.

A panel review that concludes in favour of moving still has to price the move, because switching a group health programme is not free even when the new rate is lower.

The costs that a corporate should quantify before deciding:

• Continuity of waiting-period credit. Employees who have served part of a pre-existing disease waiting period under the incumbent policy need that credit carried forward. Most insurers will grant continuity on a group transfer, but it must be confirmed in writing, at the plan level, before binding. The exposure is largest where the corporate has a workforce with long tenure and a history of chronic-condition claims.
• Ongoing treatment and open claims. Employees mid-treatment at the changeover date, and claims intimated but not settled, need an agreed handling protocol between the outgoing and incoming insurers. Left unaddressed, these become the first escalations HR receives after the switch.
• The second-year rate. A challenger insurer buying the account may quote aggressively in year one and reprice hard in year two once it has seen the claims experience. Ask for the pricing methodology and any agreed rate-revision mechanism, and treat a first-year quote well below the incumbent's as a question to investigate rather than a saving to book.

Set against those costs, the case for moving is strongest when the incumbent's answers on the service and network tests are weak in absolute terms. A slower pre-authorisation turnaround than the market matters. A three-percentage-point higher rejection rate matters. A missing tertiary-care hospital in the corporate's largest location matters. A slightly lower quote from a challenger, on its own, does not.

The defensible outcome of many panel reviews is that the corporate stays with the incumbent on improved terms, with agreed service levels written into the placement and measured quarterly. The review is what makes that improvement available. An incumbent that has held an account for a decade without competition has no reason to sharpen its terms; one that has just seen three rivals quote against it does.

Comparing group health programmes properly means comparing what each insurer's wording actually grants and excludes, not what the plan summary says. Sarvada gives commercial insurance brokers structured, searchable access to insurer policy wordings, so a broker running a group health panel review can put competing constructions side by side on the terms that decide claims. Request Access to see how structured wording comparison supports a panel recut.